197 related articles for article (PubMed ID: 1735602)
1. Plasminogen activator system in human breast cancer.
Sumiyoshi K; Serizawa K; Urano T; Takada Y; Takada A; Baba S
Int J Cancer; 1992 Feb; 50(3):345-8. PubMed ID: 1735602
[TBL] [Abstract][Full Text] [Related]
2. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Sumiyoshi K; Baba S; Sakaguchi S; Urano T; Takada Y; Takada A
Thromb Res; 1991 Jul; 63(1):59-71. PubMed ID: 1948823
[TBL] [Abstract][Full Text] [Related]
3. The plasminogen-activation system in ovarian tumors.
Pujade-Lauraine E; Lu H; Mirshahi S; Soria J; Soria C; Bernadou A; Kruithof EK; Lijnen HR; Burtin P
Int J Cancer; 1993 Aug; 55(1):27-31. PubMed ID: 8344749
[TBL] [Abstract][Full Text] [Related]
4. Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Sałuda-Gorgul A; Pytel J; Olborski B; Greger J
Z Naturforsch C J Biosci; 2002; 57(3-4):366-71. PubMed ID: 12064742
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
9. Multiple forms of plasminogen activator in human breast tumors.
O'Grady P; Lijnen HR; Duffy MJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6216-8. PubMed ID: 3933824
[TBL] [Abstract][Full Text] [Related]
10. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Foucré D; Bouchet C; Hacène K; Pourreau-Schneider N; Gentile A; Martin PM; Desplaces A; Oglobine J
Br J Cancer; 1991 Nov; 64(5):926-32. PubMed ID: 1931618
[TBL] [Abstract][Full Text] [Related]
11. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.
Nakamura M; Konno H; Tanaka T; Maruo Y; Nishino N; Aoki K; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 Mar; 65(6):709-19. PubMed ID: 1636163
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
13. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
14. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Gershtein ES; Kushlinskii NE
Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087
[TBL] [Abstract][Full Text] [Related]
15. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
16. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
17. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
19. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]